Category: Company Founded
Newly funded companies create medical innovations, help businesses improve productivity
PHILADELPHIA, PA (www.sep.benfranklin.org) – Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) recently approved investments totaling $1,800,000 for nine early-stage Pennsylvania companies with promising technology innovations. Included in this is a $500,000 investment in Molecular Detection Inc. (MDI). MDI developed a quick method to detect drug resistant Staph infections. Investment details follow.
In business, the decision to support an initiative is frequently made following a live presentation supported by slides. Too often these presentations miss the mark. Cruxio specializes in equipping biomedical companies to develop and deliver clear, powerful strategic stories - usually as live presentations. In the past four years, Cruxio's unique story-development methodology has fueled more than 50 mission-critical presentations, helping to secure more than $500 million in funds or revenue. Join Rob Wishnowsky, founder of Cruxio - the crux of the story - for an interactive overview of five essentials you need to consider to develop your clear, compelling strategic story.
In 2005 Rob Wishnowsky founded Cruxio (the crux of the story), a West Coast company that helps companies develop and deliver clear strategic stories. Cruxio's proprietary processes have been used in more than fifty presentations, securing more than $500 million in funding or revenue. Rob has extensive experience in global strategy, sales and marketing in the fields of life science, diagnostics and biotechnology. 20 years he has led business units, sales forces, strategy formulation, market segmentation, portfolio development and marketing execution, primarily in large corporations (Boehringer Mannheim/Roche Diagnostics, Johnson & Johnson's Lifescan) as well as in early-stage companies. He served on the board of the Biomedical Marketing Association from 2003 to 2007.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=206505
CONTACT:
Jeanne Mell
University City Science Center
215-966-6029
PHILADELPHIA--(June 24, 2010) – Scientists and researchers from 17 universities and research institutions in Pennsylvania, New Jersey and Delaware have been invited to submit proposals for the third round of the University City Science Center’s QED Proof-of-Concept Funding Program.
The RFP was released on June 24 to: Children’s Hospital of Philadelphia, Delaware State University, Drexel University, Fox Chase Cancer Center, Harrisburg University of Science and Technology, Lankenau Institute for Medical Research, Lehigh University, Monell Chemical Senses Center, Philadelphia College of Osteopathic Medicine, Rutgers, The State University of New Jersey, Temple University, Thomas Jefferson University, University of Delaware, University of Pennsylvania, University of the Sciences in Philadelphia, Widener University, The Wistar Institute.
Application period opens on June 21st
Contact: Angus G. McQuilken, MLSC VP for Communications
Boston, MA – Governor Patrick, the Massachusetts Life Sciences Center, MassBio and MassMEDIC today urged qualifying companies to apply for the Therapeutic Discovery Tax Credit, a new federal program created under the Affordable Care Act to support biomedical research. Qualifying companies may apply to the new federal program starting on Monday, June 21, 2010 with applications due by July 21, 2010. Applicants will receive a determination no later than October 29, 2010. More information is available on the web site of the Massachusetts Life Sciences Center, www.masslifescience.com.
CONTACT:
Jeanne Mell
University City Science Center
215-966-6029
PHILADELPHIA--(June 16, 2010) – What paths and pitfalls do growing companies face? A panel of start-up industry leaders will address the topic of managing growth as part of the University City Science Center’s Smart Talk: Adventures in Entrepreneurialism series, June 22, 2010 at 3711 Market Street in Philadelphia. The panel discussion is a follow up to remarks by Bentley Systems CEO Greg Bentley at a Smart Talk program in April.
Center Awards $1.5 million to foster job growth and technology commercialization in the Massachusetts Life Sciences Supercluster
For Immediate Release: Date: May 28, 2010
Contact: Angus G. McQuilken, MLSC VP for Communications
Phone: (617) 921-7749 Email: amcquilken@masslifesciences.com
“This is all about jobs. By helping life sciences companies grow, we create new opportunities for people to work,” said Governor Deval Patrick. “As we continue to strengthen our global leadership in the life sciences, this program will meet an important need and make Massachusetts an even more attractive place for life sciences companies to locate and grow.”
Waltham, MA – The Massachusetts Life Sciences Center’s Board of Directors today awarded $1.5 million in Small Business Matching Grants to three life sciences companies in Massachusetts. The companies receiving grants are Boston Biochem Inc. and Tetragenetics Inc., both of Cambridge and Thermedical Inc. of Somerville. Each company will receive $500,000 from the Center to match federal small business grant funding that the companies had previously been awarded. The grants represent the first round of awards issued under the Center’s Small Business Matching Grant (SBMG) Program. The three companies that are receiving awards have committed to collectively creating 40 new jobs in the Commonwealth by the end of 2011, including six jobs to be relocated from New York.
The Center’s Small Business Matching Grant Program, launched in January 2010 as part of the state’s ten-year, $1 billion Life Sciences Initiative, will match federal small business grant funding for early-stage life sciences companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts. Goals of the program include the creation of jobs in Massachusetts by the commercialization of products with high potential for market adoption and penetration.
Davis Farmer, Chairman of the Board of MSM Protein Technologies today announced that Chris Hentschel, Ph.D., has joined the Company's Board of Directors. Dr. Hentschel has served as the President and CEO of Malaria Medical Venture for the past ten years.
MMV is a not-for-profit entity based in Geneva, Switzerland that discovers, develops and delivers new and affordable therapies for malaria and assures access to those most at risk from this disease. Prior to joining MMV, Chris served as Chief Scientific Officer at Centocor where he oversaw research into a number of the products that J&J has brought to the market in recent years. He also served as the founding head of the Collaborative Centre of the UK Medical Research Council in London, a pioneering technology transfer facility designed to promote collaborations between the MRC and industry. He received his Ph.D . from King's College London, with a subsequent research fellowship from the European Molecular Biology Organization and NIH.
"Chris is a great addition to our board,” said Farmer.. “He is our first outside Director and as such will provide a valuable perspective to our decision making. He is a true visionary with a great network of relationships in the pharmaceutical, academic and finance community. He has a great track record for innovation and for the creation of successful industry collaborations. We will look to him for guidance on many fronts including strategic decisions regarding the company's long term direction."
PHILADELPHIA (May 6, 2010) – Philadelphia’s entrepreneurial culture will receive an infusion when DreamIt Ventures moves 15 emerging companies into the University City Science Center for the summer. More than 45 young entrepreneurs will spend three months working with a support team of mentors, accountants and lawyers as they work to bring their ideas to the marketplace.
DreamIt was founded in 2007 by three entrepreneurs who knew from first-hand experience that new start-ups need more than funding. So they designed a business accelerator that in addition to seed funding offers its teams a collaborative work space in the Science Center’s Quorum space; mentors and advisors; legal, accounting and administrative help; and introductions to funding sources including angel investors, venture capitalists, private investors and public sources of funding.
CONTACT:
Jeanne Mell
University City Science Center
215-966-6029
PHILADELPHIA--(May 4, 2010) – The University City Science Center has promoted Christopher J. Laing, MRCVS, Ph.D. to Vice President, Science & Technology.
Dr. Laing oversees the Science Center’s Science and Technology Programs, including the Port business incubators and the QED Proof-of-Concept Program. He also provides direct R&D strategy support to Science Center Port business incubator companies and facilitates their access to Greater Philadelphia’s academic and clinical communities through the Science Center’s Scientific Advisory Committee for the Board of Directors.
Dr. Laing began working with the Science Center as a consultant in 2004 and joined the staff as Director of Science & Technology in 2006. He has helped numerous Science Center business clients turn their academic research into thriving businesses. Dr. Laing provides guidance in early business and product development planning, in securing the resources required to retire early technology risks, and in providing a technical communication stream that includes publications, marketing, and applications to federal agencies including NIH, NSF, and FDA.
Massachusetts Lieutenant Governor Timothy Murray joins life sciences leaders for ribbon-cutting ceremony
